Array BioPharma, a biopharmaceutical company focused on targeted small molecule drugs for the treatment of cancer, has appointed John A. Orwin, CEO of Affymax, to Array's board of directors as part of its continued evolution toward late-stage development and commercialization.
Orwin has served as CEO of Affymax since 2011, after joining the company in 2010 as its COO. Previously, he held leadership roles in marketing, sales and operations for major pharmaceutical companies including Genentech, Johnson & Johnson, Alza Pharmaceuticals, Rhone-Poulenc Rorer and Schering-Plough.
Orwin brings a track record of substantial accomplishment in the pharmaceutical industry to Array's board of directors. Over his career, he has built successful businesses and commercialized a range of blockbuster products. Most recently, he led the approval and launch of Omontys, a hematology product for the treatment of anemia in chronic kidney disease. Prior to joining Affymax, he led Genentech's BioOncology business unit and grew a portfolio of cancer-fighting products including Avastin, Rituxan, Herceptin and Tarceva to over $7 billion in U.S. sales.